1997 CMS Letter to Mylan (MYL) Shows Evidence of EpiPen Medicaid Rebate - Evecore ISI's Raffat
Tweet
Share
E-mail
Get Alerts MYL Hot Sheet
Price: $15.86 --0%
Rating Summary:
17 Buy, 13 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 15 | Down: 8 | New: 36
Rating Summary:
17 Buy, 13 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 15 | Down: 8 | New: 36
Join SI Premium – FREE
Evecore ISI Mylan (NASDAQ: MYL) analyst Umer Raffat notes that while there has been considerable investor debate around whether Mylan misclassified Epipen to Medicaid, they have uncovered a letter in the public domain from CMS to Mylan from back in 1997.
In this letter, CMS recommended to Mylan that "it is entirely fitting and proper" for Mylan report Epipen as "non-innovator" to Drug Rebate Program.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Citi: 'Very high likelihood' of a positive Q1 EPS surprise
- Risks including rising dollar, bond yields and concentration problematic for stocks: JPM
- Snap (SNAP), Meta (META) gain as House orders sale or ban of TikTok
Create E-mail Alert Related Categories
Analyst Comments, Hot Comments, Short Sales, Trader TalkRelated Entities
Umer RaffatSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
